Bapineuzumab

Bapineuzumab

Monoclonal antibody
Type	Whole antibody
Source	Template:Infobox drug/mab source
Target	beta-amyloid (Aβ)
Identifiers
CAS Number	648895-38-9
ATC code	none
Chemical data
Formula	C6466H10018N1734O2026S44
Molar mass	148.8 kDa (major glycoform)[[]]

Bapineuzumab is a humanized monoclonal antibody that acts on the nervous system and has potential therapeutic value for the treatment of Alzheimer's disease and possibly glaucoma.

Bapineuzumab is an antibody to the beta-amyloid (Aβ) plaques that are believed to underlie Alzheimer's disease neuropathology. In previous clinical trials for vaccination against human beta amyloid, called AN-1792, patients with Alzheimer's disease using active immunization had positive outcomes with removal of plaques, but 6% of subjects developed aseptic meningitis and the trial was stopped.

Bapineuzumab is currently being co-developed by the pharmaceutical companies Élan and Wyeth and entered Phase III trials in December 2007.

In patients receiving the highest dose, e.g. 2 mg, MRI scans showed an accumulation of water in brain tissue (vasogenic edema). No health risks were found in subjects receiving either 0.5 or 1 mg of bapineuzumab. Patients who have been receiving or have been scheduled to receive the highest dose will be either removed from the trials or switched to lower doses.

JANSSEN Alzheimer Immunotherapy, a Johnson & Johnson affiliate, had acquired substantially all of Elan’s assets related to the Alzheimer’s Immunotherapy Program (AIP), which Elan had shared with Wyeth.JANSSEN Alzheimer Immunotherapy is continuing the AIP activities with Pfizer, which acquired Wyeth in 2009.

References

ru:Бапинейзумаб